Abstract:OBJECTIVE:To conduct a systematic review and meta-analysis of randomized controlled trials (RCTs) that have assessed the effect and safety of ursodeoxycholic acid (UDCA), S-adenosylmethionine (SAMe) and UDCA-SAMe combination therapies for intrahepatic cholestasis of pregnancy (ICP).METHODS:Using searching protocols and assessment methods recommended by the Cochrane Collaboration to reduce bias in systematic reviews, the databases of Medline, EMBASE, Cochrane Central Register of Controlled Trials (CCRT), China National Knowledge Infrastructure (CNKI), Chinese BioMedical Literature (CBM) and Wanfang China Online Journals were searched to identify relevant RCTs published from database inception to December 2011.RESULTS:Ten RCTs (of 727 pregnant women) were included in the study and represented a low risk for bias. Compared to the patients who received UDCA monotherapy, those who received UDCA-SAMe combination therapy had significantly lower rates of Cesarean section (odds ratio (OR) =0.45, 95% confidence interval (CI):0.24-0.86), preterm birth (OR=0.36, 95% CI:0.20-0.63), and fetal asphyxia (OR=0.27, 95% CI:0.13-0.56) (all P less than 0.05); however, the UDCA-SAMe therapy did not provide better rates of amniotic fluid pollution (OR=0.38, 95% CI:0.14-1.01) or better new bom weight (mean difference (MD) =397.36, 95% CI:-96.17-890.89). Compared to the patients who received SAMe monotherapy, those who received UDCA-SAMe combination therapy had significantly lower rates of preterm birth (OR=0.39, 95% CI:0.21-0.73), fetal asphyxia (OR=0.23, 95% CI:0.07-0.75), and amniotic fluid pollution (OR=0.41, 95% CI:0.20-0.85) (all, P less than 0.05); however, the UDCA-SAMe therapy did not provide better rates of Cesarean section (OR =0.62, 95% CI:0.27-1.44) or better new bom weight (MD =445.95, 95% CI:-143.51-1035.42). Comparison of the two monotherapies (UCDA vs.SAMe) showed no statistical differences in rates of Cesarean section (OR=0.91, 95% CI:0.47-1.78), preterm birth (OR =0.79, 95% CI:0.49-1.38), fetal asphyxia (OR=0.90, 95% CI:0.38-2.12), and amniotic fluid pollution (OR=1.14, 95% CI:0.61-2.13), as well as of new born weight (MD =-62.86, 95% CI:-157.81-32.09). Six studies reported no side effects.None of the included studies reported use of allocation concealment or blinding.CONCLUSION:UDCA-SAMe combination therapy is better than either UDCA or SAMe monotherapy for improving the outcome of ICP without adverse effects. Large-scale trials with adequate sample sizes and higher quality study design are needed to further confirm the efficiency and safety of UDCA and SAMe for treating ICP.

Clinical observation of succinic acid adenosine methionine enteric-coated tablet in treatment of intrahepatic cholestasis during pregnancy

Ursodeoxycholic Acid and S-adenosylmethionine for the Treatment of Intrahepatic Cholestasis of Pregnancy: A Meta-analysis.

A clinical observation of therapeutic effect of combined heparin for intrahepatic cholestasis of pregnancy

[Meta-Analysis of Ursodeoxycholic Acid and S-adenosylmethionine for Improving the Outcomes of Intrahepatic Cholestasis of Pregnancy].

Treatment Of Intrahepatic Cholestasis Of Pregnancy Using Ursodeoxycholic Acid: A Meta-Analysis

Study on the changes of RBC, Hct, and Ret levels in patients with anemia during pregnancy and clinical treatment

[Effect of Integrative Chinese and Western Medicine in Treating Pregnant Women with Intrahepatic Cholestasis].

Clinical Observation on Alcoholic Cirrhosis Treated with Method for Dissipating Phlegm and Removing Blood Stasis

Level of Serum MDA and Vitamin E of Patients with Intrahepatic Cholestasis of Pregnancy

A Clinical Analysis of the Rapeutic Effect for 126 Cases of ICP

Analysis on the efficacy of the combination of TCM and Western Medicine in treating intrahepatic cholestasis of pregnancy with different degree

Evaluation of neopterin,soluble interleukin-2 receptor and T-helper cell in intrahepatic cholestasis of pregnancy

Pharmacokinetics and food impact assessment of ademetionine enteric‐coated tablet as an endogenous substance drug in healthy Chinese volunteers

[Effects of Ursodeoxycholic Acid on the Liver Plasma Membrane Fluidity, Hepatic Glutathione Concentration, Hepatic Estrogen Receptors and Progesterone Receptors in Pregnant Rats with Ethinylestradiol and Progesterone Induced Intrahepatic Cholestasis].

Clinical Analysis of 240 Cases of Intrahepatic Cholestasis of Pregnancy

A Retrospective, Multi-Center, Post-Marketing Observational Study to Evaluate the Effectiveness of Ademetionine 1,4-Butanedisulfonate Injection (transmetil®) Treatment in Chinese Patients with Intrahepatic Cholestasis Caused by Viral Hepatitis

Effects of Ursodeoxycholic Acid on Intrahepatic Cholestasis in Rats

Efficacy of Ursodeoxycholic Acid in Treatment of High Level Glycocholic Acid During Pregnancy

GSH-PX,LPO and SOD Levels in Pregnant Women with Intrahepatic Cholestasis and Their Clinical Significance

Comparative Evidence for Intrahepatic Cholestasis of Pregnancy Treatment with Traditional Chinese Medicine Therapy: A Network Meta-Analysis

Effect of ursodeoxycholic acid and olynicate and naphthylactic acid on chronic hepatitis B and intrahepatic cholestasis